Chest:重症监护期间新诊断的房颤的长期影响

2019-05-07 xing.T 网络

由此可见,无论AF复发和重症监护的原因如何,在重症监护期间新诊断AF后存活的患者长期卒中/SE和死亡率的风险仍高于无AF患者。这些患者可能需要密切随访和持续抗凝治疗。

在重症监护期间新诊断房颤(AF)幸存者中,血栓栓塞和死亡的长期风险尚不清楚。近日,呼吸领域权威杂志chest上发表了一篇研究文章,研究人员通过使用韩国国民健康保险服务数据库,确定了30869名成年人,他们在重症监护期间(ICU-AF)新诊断AF后存活超过6个月,269751名非ICU AF对照者(AF对照者)和439868名非AF对照者(No-AF),研究人员进行了倾向评分匹配并比较了卒中/全身栓塞(SE)和全因死亡率的风险。

与AF对照者和No-AF组相比,ICU-AF患者的长期卒中/SE的校正风险比(HR)分别为0.93(95%可信区间[CI]为0.88-0.98)和1.50(95%CI为1.42-1.60)。与AF对照组和无AF组相比,ICU-AF组长期死亡率的校正HR分别为1.73(95%CI为1.70-1.83)和3.20(95%CI为3.08-3.33)。ICU-AF组卒中/SE和死亡风险显著高于No-AF组,排除AF复发患者(调整HR为1.08; 95%CI为1.01-1.17),无论其原因如何重症监护和血管或非血管手术。 

由此可见,无论AF复发和重症监护的原因如何,在重症监护期间新诊断AF后存活的患者长期卒中/SE和死亡率的风险仍高于无AF患者。这些患者可能需要密切随访和持续抗凝治疗。 

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1915293, encodeId=fce5191529307, content=<a href='/topic/show?id=e381586e94d' target=_blank style='color:#2F92EE;'>#新诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58679, encryptionId=e381586e94d, topicName=新诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Wed Nov 13 18:43:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051374, encodeId=2a1b20513e4a8, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Oct 11 14:43:00 CST 2019, time=2019-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053275, encodeId=5ae320532e5d1, content=<a href='/topic/show?id=6d7796998e0' target=_blank style='color:#2F92EE;'>#长期影响#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96998, encryptionId=6d7796998e0, topicName=长期影响)], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/cc81592b507031e3cfd8d4c57911d98b/62c22832a9474aea1ca90ca058aebc03.jpg, createdBy=bed5446, createdName=limedical1974, createdTime=Fri Dec 06 01:43:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929558, encodeId=7502192955803, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Wed Jul 10 21:43:00 CST 2019, time=2019-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551152, encodeId=9df71551152b2, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Wed May 08 22:43:00 CST 2019, time=2019-05-08, status=1, ipAttribution=)]
    2019-11-13 rgjl
  2. [GetPortalCommentsPageByObjectIdResponse(id=1915293, encodeId=fce5191529307, content=<a href='/topic/show?id=e381586e94d' target=_blank style='color:#2F92EE;'>#新诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58679, encryptionId=e381586e94d, topicName=新诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Wed Nov 13 18:43:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051374, encodeId=2a1b20513e4a8, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Oct 11 14:43:00 CST 2019, time=2019-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053275, encodeId=5ae320532e5d1, content=<a href='/topic/show?id=6d7796998e0' target=_blank style='color:#2F92EE;'>#长期影响#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96998, encryptionId=6d7796998e0, topicName=长期影响)], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/cc81592b507031e3cfd8d4c57911d98b/62c22832a9474aea1ca90ca058aebc03.jpg, createdBy=bed5446, createdName=limedical1974, createdTime=Fri Dec 06 01:43:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929558, encodeId=7502192955803, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Wed Jul 10 21:43:00 CST 2019, time=2019-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551152, encodeId=9df71551152b2, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Wed May 08 22:43:00 CST 2019, time=2019-05-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1915293, encodeId=fce5191529307, content=<a href='/topic/show?id=e381586e94d' target=_blank style='color:#2F92EE;'>#新诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58679, encryptionId=e381586e94d, topicName=新诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Wed Nov 13 18:43:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051374, encodeId=2a1b20513e4a8, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Oct 11 14:43:00 CST 2019, time=2019-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053275, encodeId=5ae320532e5d1, content=<a href='/topic/show?id=6d7796998e0' target=_blank style='color:#2F92EE;'>#长期影响#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96998, encryptionId=6d7796998e0, topicName=长期影响)], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/cc81592b507031e3cfd8d4c57911d98b/62c22832a9474aea1ca90ca058aebc03.jpg, createdBy=bed5446, createdName=limedical1974, createdTime=Fri Dec 06 01:43:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929558, encodeId=7502192955803, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Wed Jul 10 21:43:00 CST 2019, time=2019-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551152, encodeId=9df71551152b2, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Wed May 08 22:43:00 CST 2019, time=2019-05-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1915293, encodeId=fce5191529307, content=<a href='/topic/show?id=e381586e94d' target=_blank style='color:#2F92EE;'>#新诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58679, encryptionId=e381586e94d, topicName=新诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Wed Nov 13 18:43:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051374, encodeId=2a1b20513e4a8, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Oct 11 14:43:00 CST 2019, time=2019-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053275, encodeId=5ae320532e5d1, content=<a href='/topic/show?id=6d7796998e0' target=_blank style='color:#2F92EE;'>#长期影响#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96998, encryptionId=6d7796998e0, topicName=长期影响)], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/cc81592b507031e3cfd8d4c57911d98b/62c22832a9474aea1ca90ca058aebc03.jpg, createdBy=bed5446, createdName=limedical1974, createdTime=Fri Dec 06 01:43:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929558, encodeId=7502192955803, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Wed Jul 10 21:43:00 CST 2019, time=2019-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551152, encodeId=9df71551152b2, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Wed May 08 22:43:00 CST 2019, time=2019-05-08, status=1, ipAttribution=)]
    2019-07-10 Smile2680
  5. [GetPortalCommentsPageByObjectIdResponse(id=1915293, encodeId=fce5191529307, content=<a href='/topic/show?id=e381586e94d' target=_blank style='color:#2F92EE;'>#新诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58679, encryptionId=e381586e94d, topicName=新诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Wed Nov 13 18:43:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051374, encodeId=2a1b20513e4a8, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Oct 11 14:43:00 CST 2019, time=2019-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053275, encodeId=5ae320532e5d1, content=<a href='/topic/show?id=6d7796998e0' target=_blank style='color:#2F92EE;'>#长期影响#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96998, encryptionId=6d7796998e0, topicName=长期影响)], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/cc81592b507031e3cfd8d4c57911d98b/62c22832a9474aea1ca90ca058aebc03.jpg, createdBy=bed5446, createdName=limedical1974, createdTime=Fri Dec 06 01:43:00 CST 2019, time=2019-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929558, encodeId=7502192955803, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Wed Jul 10 21:43:00 CST 2019, time=2019-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551152, encodeId=9df71551152b2, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Wed May 08 22:43:00 CST 2019, time=2019-05-08, status=1, ipAttribution=)]
    2019-05-08 bioon6

相关资讯

一天监护34小时 陕西一医院被曝乱收费

患者家属质疑医院每日清单有“蹊跷”,延安大学咸阳医院核退部分费用。

荣总医院心肺康复中心林克隆教授:医学为生命增加岁月,康复让岁月增添生命

来自高雄荣民总医院林克隆教授介绍了其所在医院心肺康复中心所做的工作和经验。

Crit Care Med:外科重症监护患者铁调素和贫血!

由此可见,入住ICU时铁调素血清浓度明显增加,并在ICU停留期间(28天)显著降低。降低的铁调素浓度与增加的网织红细胞反应和通过减少IL-6和C反应蛋白浓度来体现减弱的炎症反应有关,但与贫血痊愈无关。

Lancet respir med:区分疾病亚型有助于精准医疗改善患者预后

以疾病亚型为基础的精准医疗方法已经改变了癌症、哮喘以及其他异质性综合征的治疗策略。3个US临床试验已经证实急性呼吸窘迫综合征(ARDS)有2种不同的亚型,该两种亚型对呼气末正压通气和液体管理的反应截然不同。现有研究人员探究该两种亚型是否存在非美人群以及其对药物治疗的反应是否存在差异。HARP-2是在英国和爱尔兰的40家医院的普通重症监护室(ICUs)开展一多中心的随机对照试验,评估辛伐他汀(80m

Pediatr Crit Care Med:右美托咪啶作为单次连续镇静药物用于无创通气:经典用法、血流动力学影响及戒断反应

右美托咪定儿科重症监护中的应用正在增加,作为单一镇静药物连续用药其长期作用并没有得到很好描述。本研究的目的是在不存在其他持续镇静情况下,描述长期应用右美托咪定治疗下的血流动力学效应,停用策略,以及戒断的危险因素。

Chest:PPI与H2B在预防重症监护患者消化道大出血的疗效比较!

由此可见,在重症患者中,与PPIs相比,H2Bs可以稳定并且显著降低CIGIB的风险。